alexa The prostate-specific antigen test.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Roobol MJ

Abstract Share this page

Abstract Before the 1980s, prostate cancer (PC) was considered a deadly disease. The mortality-incidence ratio showed that 1 out of each 2 - 3 PC patients died of this disease. On the other hand, autopsy studies have shown that latent PC is common in middle-aged men. The prostate-specific antigen (PSA), a glycoprotein produced by the epithelial cells of the prostate gland, received FDA's approval in 1986 for monitoring treatment response, and in 1994 as a screening aid for the diagnosis of PC. After the publication of two randomized trials on PC screening using the PSA test, it is generally accepted that systematic PSA-based screening, as compared to a clinical situation with virtually no screening, can reduce suffering from metastatic disease and PC mortality. However, what is also shown is that PSA-based screening coincides with a considerable amount of unnecessary testing and overdiagnosis. Should we abandon the use of the PSA test for the diagnosis of PC, or should we encourage PSA testing and make it freely available for all men at any time? Both the answers should be "No." What we must do is use the test as wisely as is currently possible and inform men, who want to be tested, in a balanced way about harms and potential benefits. This article was published in Expert Opin Med Diagn and referenced in Journal of Diabetes & Metabolism

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords